Novartis logo.
RLT Institute
An illustration depicting radioligand therapy facilities and equipment, including radiation warning signs, a treatment chair, and space schematics.

Facilities and equipment

This section of the Novartis RLT Institute reviews the considerations in setting up the facilities and equipment required to provide radioligand therapy (RLT).

Facility considerations

Overview

Facilities with specific radiation safety considerations are needed for the administration of RLTs.1

An illustration of a collection of people representing health care providers, patients, and the public.

Prioritizing safety

These spaces are designed to collectively support a safe environment for patients, health care providers, and the public, ensuring compliance with Nuclear Regulatory Commission (NRC) and any local regulations in order to minimize unnecessary radiation exposure.1

An illustration of the entrance to a radioligand therapy facility with radiation warning signs.

Design for program needs

The design and requirements of these spaces depend on the specific treatments offered and patient volumes, but all facilities must meet NRC standards and/or local regulation requirements, to protect public health and safety.2

By carefully tailoring the facility layout and equipment to align with these needs, health care providers can create a safe and compliant environment for delivering RLTs.

The information included in this module is for guidance and illustrative purposes only; every space is unique and will require consideration on an individual basis.

The information herein is intended to assist practitioners in providing appropriate care for patients when using radiopharmaceuticals. This information is not intended to establish, nor should it be used to establish, a legal standard of care. It is important to adhere to all applicable standards when handling and administering radiopharmaceuticals. Institutions are responsible for ensuring their compliance with all laws and regulations by establishing their own policies, procedures, and guidance. Novartis Pharmaceuticals Corporation does not endorse or recommend any specific course of action, or any third-party organization referenced herein.
RLT facility needs
Up Next